Close
Presentations (slides, Video) and Abstract are available to GBCC Sign-up members.
You can access after log-in.
Program
Scientific Program
Program at a Glance
Scientific Program
Invited Speakers
09:00-10:15
  • Symposium 1: 
    Recent Strategies for ER+/HER2- Breast Cancer6
  • Venue:  RM 1(Vista 1+2)
Moderators
  • Young-Jin Suh
     (The Catholic Univ. of Korea, St. Vincent's Hospital, Korea)
  • Peter C. Dubsky
     (Hirslanden Klinik St. Anna, Switzerland)
Speakers
  • Optimal Duration of Endocrine Therapy
    Polly Suk Yee Cheung
     (Hong Kong Sanatorium and Hospital, Hong Kong)
  • The Role of CDK4/6 Inhibitors in ER+/HER2- Early Breast Cancer
    Tadahiko Shien
     (Okayama Univ. Hospital, Japan)
  • ER+/HER2 Negative Premenopausal Breast Cancer- The Biomarker Way Forward
    Peter C. Dubsky
     (Hirslanden Klinik St. Anna, Switzerland)
  • Panel Discussion 1: 
    How to Manage Old-aged Breast Cancer Patients?15
  • Venue:  RM 2(Vista 3)
Moderators
  • Jee Hyun Kim
     (Seoul National Univ. Bundang Hospital, Korea)
  • Eun Sook Lee
     (National Cancer Center, Korea)
Speakers
  • Screening and Assessment of Breast Cancer in Older Women
    Lester Leong
     (Singapore General Hospital, Singapore)
  • Systemic Therapy for Older Breast Cancer Patients
    Jee Hyun Kim
     (Seoul National Univ. Bundang Hospital, Korea)
  • Surgical Therapy for Older Breast Cancer Patient
    Tristen Park
     (Yale School of Medicine, U.S.A.)
  • Education Session 1: 
    Radiologist’s Perspectives on Neoadjuvant Systemic Therapy in Breast Cancer21
  • Venue:  RM 3(Walker Hall 1)
Moderators
  • Hak Hee Kim
     (ASAN Medical Center, Korea)
  • Boo-Kyung Han
     (Samsung Medical Center, Korea)
Speakers
  • Causes of Over- and Underestimation of Tumor and Axillary LN After Neoadjuvant System Therapy
    Beatriu Reig
     (NYU Langone Health, U.S.A.)
  • Evaluation of Response to Neoadjuvant Systemic Therapy: Multiparametric Approach for Accurate Evaluation of Residual Tumor
    Masako Kataoka
     (Kyoto Univ., Japan)
  • How to Manage Residual Microcalcifications After Neoadjuvant Chemotherapy
    Sung Hun Kim
     (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
  • Oral Presentation 1
    51
  • Venue:  RM 4(Walker Hall 2)
Speakers
  • BREAST CANCER IN ADOLESCENT & YOUNG ADULT (AYA) AGE GROUP HAS A SPECIFIC BIOLOGICAL FEATURE AND POOR OUTCOME COMPARED TO OTHER GENERATIONS
    Masanori Oshi
     (Yokohama City University Graduate School of Medicine, Japan)
  • CONSECUTIVE GAIN AND LOSS IN BODY WEIGHT AND WAIST CIRCUMFERENCE WITH RISK OF SUBSEQUENT BREAST CANCER IN KOREAN WOMEN
    Thi Xuan Mai Tran
     (Hanyang Univ. College of Medicine, Vietnam)
  • THE BURDEN OF BREAST CANCER IN YOGYAKARTA SPECIAL REGION, INDONESIA FROM 2008-2019: A TEMPORAL TREND ANALYSIS OF THE POPULATION-BASED CANCER REGISTRY DATA
    Herindita Puspitaningtyas
     (Faculty Of Medicine, Public Health And Nursing, Universitas Gadjah Mada,Yogyakarta, Indonesia)
  • AUGMENTING BREAST CANCER SCREENING EFFICIENCY BY MAXIMIZING DETECTION OF NORMAL MAMMOGRAMS USING AN ARTIFICIAL INTELLIGENCE ALGORITHM
    Serene Si Ning Goh
     (National Univ. of Singapore, Singapore)
  • THE EFFECT OF MAMMOGRAPHIC BREAST DENSITY ON DIAGNOSTIC OUTCOMES IN MEN
    Hwan Lee
     (Univ. of Pennsylvania, U.S.A.)
  • DRUG-RESISTANT EXTRACELLULAR VESICLES PREDICT TUMOR RESPONSE IN BREAST CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY
    Jee Ye Kim
     (Yonsei Univ. College of Medicine, Korea)
  • DEEP LEARNING-BASED QUANTITATIVE ESTIMATION OF LYMPHEDEMA-INDUCED FIBROSIS USING THREE-DIMENSIONAL COMPUTED TOMOGRAPHY IMAGES
    Chang Ho Hwang
     (Chungnam National Univ. College of Medicine, Korea)
  • PROGNOSTIC VALUE OF THE NGS-BASED MULTIGENE ASSAY TO PREDICT DISTANT METASTASIS IN HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER: ANALYSIS OF THE DEVELOPMENT COHORT WITH A FOLLOW-UP OF 95 MON
    Eunhye Kang
     (Seoul National Univ. Hospital, Korea)
  • FEASIBILITY AND HEALTH OUTCOMES OF HOME-BASED AEROBIC AND RESISTANCE TRAINING IN INDONESIAN BREAST CANCER PATIENTS
    Yufi Kartika Astari
     (Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia)
  • GBCC-SSO Joint Session: 
    Management of Hereditary Breast Cancer - Global Perspectives of Surgical Oncologists41
  • Venue:  RM 5(Art Hall)
Moderators
  • Jeong Eon Lee
     (Samsung Medical Center, Korea)
  • Tolga Ozmen
     (Massachusetts General Hospital, U.S.A.)
Speakers
  • Management of Hereditary Breast Cancer in the U.S.
    Tolga Ozmen
     (Massachusetts General Hospital, U.S.A.)
  • Management of Hereditary Breast Cancer in Europe
    Isabel T. Rubio
     (Clinica Universidad de Navarra, Spain)
  • Management of Hereditary Breast Cancer in Asia
    Sung-Won Kim
     (Daerim St. Mary's Hospital, Korea)
10:30-11:45
  • Symposium 2: 
    HER2-Low as a Targetable Subset of Breast Cancer7
  • Venue:  RM 1(Vista 1+2)
Moderators
  • Kyong Hwa Park
     (Korea Univ. Anam Hospital, Korea)
  • Naoto Ueno
     (Univ. of Hawai'i Cancer Center, U.S.A.)
Speakers
  • Is HER2-Low Breast Cancer an Independent/Distinctive Subtype?
    Naoto Ueno
     (Univ. of Hawai'i Cancer Center, U.S.A.)
  • How to Identify HER2-Low Breast Cancer
    Hee Jin Lee
     (ASAN Medical Center, Korea)
  • Targeting HER2-Low and the Treatment Sequence
    Wei-Pang Chung
     (National Cheng Kung Univ. Hospital, Taiwan)
  • Panel Discussion 2: 
    Various Considerations in Premenopausal Breast Cancer Patients16
  • Venue:  RM 2(Vista 3)
Moderators
  • Min Sung Chung
     (Hanyang Univ. Seoul Hospital, Korea)
  • Eric Schneider
     (Yale School of Medicine, U.S.A.)
Speakers
  • The Optimal Endocrine Combination with OFS
    Hee Jeong Kim
     (ASAN Medical Center, Korea)
  • Targeted Therapy for High-risk Patients and gBRCA Mutation Patients
    Hee Kyung Ahn
     (Gachon Univ. Gil Medical Center, Korea)
  • Prophylactic Mastectomy
    Eric Schneider
     (Yale School of Medicine, U.S.A.)
  • Education Session 2: 
    Genomic Assays and Treatment Decision22
  • Venue:  RM 3(Walker Hall 1)
Moderators
  • Hyun Jo Youn
     (Jeonbuk National Univ. Hospital, Korea)
  • Kevin Kalinsky
     (Winship Cancer Institute of Emory Univ., U.S.A.)
Speakers
  • Optimal Decisions on Adjuvant Endocrine and Chemotherapy Using Multigene Assays
    Chi-Cheng Huang
     (Taipei Veterans General Hospital, Taiwan)
  • Clinical Parameters as Alternatives to Genomic Assays
    Jong Won Lee
     (ASAN Medical Center, Korea)
  • Interpretation of Genomic Assays in Premenopausal Women
    Kevin Kalinsky
     (Winship Cancer Institute of Emory Univ., U.S.A.)
  • Oral Presentation 2
    52
  • Venue:  RM 4(Walker Hall 2)
Speakers
  • GENOMIC CHARACTERIZATION OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER WITH HIGH TUMOR MUTATIONAL BURDEN: FRESH-FROZEN TISSUE GENOMIC ANALYSIS FROM MUTATION-1 STUDY (KCSG BR17-04)
    Min Hwan Kim
     (Yonsei Univ. College of Medicine, Korea)
  • BROWN ADIPOCYTE FACILITATES BREAST CANCER INVASIVENESS VIA CELL FUSION
    Shihang Hu
     (The Univ. of Hong Kong, Hong Kong)
  • COMBINATION OF LOCAL RADIOTHERAPY AND ANTI-GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) THERAPY AUGMENTS PD-L1 BLOCKADE-MEDIATED ANTI-TUMOR EFFECTS IN MURINE BREAST CANCER MODEL
    Jun Yeong Song
     (Seoul National Univ. Hospital, Korea)
  • COMPARISON OF TRANSCRIPTOME PROFILES BETWEEN HER2-LOW AND HER2-ZERO BREAST CANCER
    Po-Hsiang Huang
     (National Taiwan University Hospital, Taiwan)
  • GERMLINE MUTATIONS RELATED TO COMPLETE REMISSION AFTER NEOADJUVANT THERAPY DETECTED BY MULTIGENE PANELS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
    Jee Hyun Ahn
     (Yonsei Univ. College of Medicine, Korea)
  • EXPLORATION OF MELK AS A DOWNSTREAM OF DEL-1 & DRUGGABLE TARGET IN TNBC
    In Hee Lee
     (Kyungpook National Univ. Chilgok Hospital, Korea)
  • SYMPTOM CLUSTER AND PREDICTORS OF GENERAL CHEMOTHERAPY TOXICITY IN PATIENTS WITH BREAST CANCER: EXPLORATORY FACTOR ANALYSIS (EFA) AND A CHI-SQUARE AUTOMATIC INTERACTION DETECTOR (CHAID) DECISION TREE
    Juan Adrian Wiranata
     (Master Of Clinical Epidemiology Postgraduate Program, Indonesia)
  • B-CELL MEDIATED IMMUNITY PREDICTS SURVIVAL OF ER-POSITIVE BREAST CANCER
    Byung-Hee Kang
     (Seoul National Univ. Bundang Hospital, Korea)
  • IMPROVEMENT OF DIAGNOSTIC ACCURACY OF BREAST CANCER USING MULTI-PROTEIN SIGNATURE MARKERS THROUGH MACHINE LEARNING
    Yumi Kim
     (CHA Gangnam Medical Center, Korea)
  • GBCC-JBCS Joint Session: 
    Holistic Management for Breast Cancer Patients in Pandemic Era42
  • Venue:  RM 5(Art Hall)
Moderators
  • Sung Yong Kim
     (Soonchunhyang Univ. Hospital Cheonan, Korea)
  • Hiroko Bando Tamura
     (Univ. of Tsukuba, Japan)
Speakers
  • Present and Future Perspectives in Korea
    So-Youn Jung
     (National Cancer Center, Korea)
  • Present and Future Perspectives in Japan
    Akihiko Shimomura
     (National Center for Global Health and Medicine, Japan)
Panelist
  • Discussion
    Beom Seok Kwak
     (Dongguk Univ. Ilsan Hospital, Korea)
  • In Hae Park
     (Korea Univ. Guro Hospital, Korea)
  • Fumikata Hara
     (Cancer Institute Hospital of JFCR, Japan)
12:00-12:45
  • Plenary Lecture 1
    1
  • Venue:  RM 1(Vista 1+2)
Moderators
  • Seock-Ah Im
     (Seoul National Univ. Hospital, Korea)
Speakers
  • A Revolution in the Making: How Antibody-Drug Conjugates are Transforming Breast Cancer Treatment
    Ian Krop
     (Yale School of Medicine, U.S.A.)
13:00-13:45
  • Satellite Symposium 1: 
    MSD Korea45
  • Venue:  RM 1(Vista 1+2)
Moderators
  • TBD
     (, )
Speakers
  • Pembrolizumab for More TOMORROWs in TNBC
    Yen-Shen Lu
     (National Taiwan Univ. Hospital, Taiwan)
14:00-14:45
  • Plenary Lecture 2
    2
  • Venue:  RM 1(Vista 1+2)
Moderators
  • Joohyuk Sohn
     (Yonsei Cancer Center, Korea)
Speakers
  • Fertility Issues in Young Breast Cancer Patients
    Sibylle Loibl
     (GBG Forschungs GmbH, Germany)
15:00-16:15
  • Panel Discussion 3: 
    Optimal Surgical Treatment After Neoadjuvant Chemotherapy17
  • Venue:  RM 2(Vista 3)
Moderators
  • Jun Won Min
     (Dankook Univ. Hospital, Korea)
  • Christoph Tausch
     (Breast-Center Zurich, Switzerland)
Speakers
  • Avoiding Breast Surgery in Patients with Radiologic Complete Response
    Christoph Tausch
     (Breast-Center Zurich, Switzerland)
  • De-escalation of Sentinel Lymph Node Biopsy in Patients with Radiologic Complete Response
    Shih-Che Shen
     (Chang Gung Memorial Hospital, Taiwan)
  • De-escalation of Radiotherapy in Patients Achieved Pathologically Complete Response
    Yeon-Joo Kim
     (National Cancer Center, Korea)
  • Symposium 3: 
    Beyond CDK4/6 Inhibitor: New Target and New Drugs8
  • Venue:  RM 3(Walker Hall 1)
Moderators
  • Jin-Hee Ahn
     (ASAN Medical Center, Korea)
  • Nadia Harbeck
     (LMU Univ. Hospital, Germany)
Speakers
  • Novel Oral SERD and its Implication in Clinical Practice
    Yen-Shen Lu
     (National Taiwan Univ. Hospital, Taiwan)
  • Treatment Strategy After Progression on CDK4/6 Inhibitor
    Nadia Harbeck
     (LMU Univ. Hospital, Germany)
  • New Targets Beyond CDK4/6 Inhibitor: Development in Progress
    Yong Wha Moon
     (CHA Bundang Medical Center, Korea)
  • Oral Presentation 3
    53
  • Venue:  RM 4(Walker Hall 2)
Speakers
  • IMPACT OF RESIDUAL MICROCALCIFCATIONS ON PROGNOSIS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
    Eun Young Kim
     (Kangbuk Samsung Hospital, Korea)
  • IS AGE AN INDEPENDENT FACTOR OF LATE RECURRENCE AMONG YOUNG BREAST CANCER PATIENTS WITH ESTROGEN RECEPTOR POSITIVE/HER2 NEGATIVE?
    Dong Seung Shin
     (Samsung Medical Center, Korea)
  • STROMAL TUMOR INFILTRATING LYMPHOCYTES (TIL) AS A POTENTIAL PROGNOSTIC BIOMARKER FOR RECURRENCE IN LOCALLY ADVANCED BREAST CANCER (LABC) PATIENTS
    Dannu Novriandhika
     (Medical Faculty Airlangga University, Dr Soetomo General Hospital Surabaya, Indonesia)
  • DEVELOPMENT OF BREAST CANCER RISK PREDICTION MODEL INCORPORATING POLYGENIC RISK SCORE AND NONGENETIC RISK FACTORS IN KOREAN WOMEN
    Jihye Choi
     (National Medical Center, Korea)
  • LONG-TERM PROGNOSTIC VALUE OF THE GENESWELL BCT SCORE IN ASIAN WOMEN WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER
    Youngwon Lee
     (ASAN Medical Center, Korea)
  • ESTABLISHING THE CORRELATION OF AN 8-GENE SET OF IMMUNE-RESPONSE GENE EXPRESSION PROFILING WITH PATHOLOGICAL COMPLETE RESPONSE NEOADJUVANT CHEMOTHERAPY IN PRIMARY BREAST CANCER PATIENTS
    Chun-Yu Liu
     (Taipei Veterans General Hospital, Taiwan)
  • THE EFFECT OF PROGESTERONE RECEPTOR EXPRESSION LEVEL TO PREDICT PROGNOSIS OF ESTROGEN RECEPTOR POSITIVE/ HER2 NEGATIVE YOUNG BREAST CANCER: A SINGLE-CENTER PROSPECTIVE COHORT STUDY.
    Youngji Kwak
     (Samsung Medical Center, Korea)
  • ELUCIDATING THE MUTATIONAL LANDSCAPE OF PI3K PATHWAY AMONG INDIAN BREAST CANCER CASES.
    Rahul Kumar
     (All India Institute of Medical Sciences, New Delhi, India)
  • GBCC-TBCS Joint Session: 
    Making Evidences Together43
  • Venue:  RM 5(Art Hall)
Moderators
  • Hyun Jo Youn
     (Jeonbuk National Univ. Hospital, Korea)
  • Chiun-Sheng Huang
     (National Taiwan Univ. Hospital, Taiwan)
Speakers
  • Breast Cancer Registry from the Korean Breast Cancer Society
    Jaihong Han
     (National Cancer Center, Korea)
  • Nationwide Taiwanese Breast Cancer Study
    Ching-Hung Lin
     (National Taiwan Univ. Hospital, Taiwan)
  • Korean Breast Cancer Study Using National Insurance Big Data
    Sungmin Park
     (Chungbuk National Univ. Hospital, Korea)
Panelist
  • Discussion
    Soo Youn Bae
     (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
  • Zisun Kim
     (Soonchunhyang Univ. Hospital Bucheon, Korea)
  • Shin-Cheh Chen
     (Chang Gung Memorial Hospital, Taiwan)
  • Fang-Ming Chen
     (Kaohsiung Municipal Ta-Tung Hospital, Taiwan)
16:30-17:45
  • Education Session 3: 
    Special Issues in Young Women with Breast Cancer Treated with Radiotherapy23
  • Venue:  RM 2(Vista 3)
Moderators
  • Yong Bae Kim
     (Yonsei Cancer Center, Korea)
  • Haeyoung Kim
     (Samsung Medical Center, Korea)
Speakers
  • Breast Radiotherapy During Pregnancy
    Stefanie Corradini
     (Univ. Hospital, LMU Munich, Germany)
  • Risk of Contralateral Breast Cancer After Breast Radiotherapy in Young Women
    Seung Won Seol
     (Univ. of Pennsylvania, U.S.A.)
  • Heart Disease After Breast Radiotherapy in Young Women
    Ji Hyeon Joo
     (Pusan National Univ. Yangsan Hospital, Korea)
  • Symposium 4: 
    Tailored Surgery in Early-stage Breast Cancer9
  • Venue:  RM 3(Walker Hall 1)
Moderators
  • Yongsik Jung
     (Ajou Univ. Hospital, Korea)
  • Caroline Drukker
     (Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Netherlands)
Speakers
  • Individualized Surgical Extent and Lumpectomy Margin in Early-stage Breast Cancer: Does Tumor Histology and Subtype Matter?
    Naoki Hayashi
     (Showa Univ. School of Medicine, Japan)
  • The Role of Axillary Surgery for DCIS and Early-stage Breast Cancer
    Wonshik Han
     (Seoul National Univ. Hospital, Korea)
  • Pre-operative Genomic Assay for Breast Surgery Guidance in HR+/HER2- Breast Cancer
    Caroline Drukker
     (Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Netherlands)
  • Oral Presentation 4
    54
  • Venue:  RM 4(Walker Hall 2)
Moderators
  • Okhee Woo
     (Korea Univ. Guro Hospital, Korea)
  • Hyung Seok Park
     (Yonsei Univ. College of Medicine, Korea)
Speakers
  • NATIONAL PATTERNS OF HOSPITAL ADMISSION VS HOME RECOVERY FOLLOWING MASTECTOMY FOR BREAST CANCER
    Leah Kim
     (Yale University School of Medicine, U.S.A.)
  • IMPACT OF DISTANCE BETWEEN TUMOR AND NIPPLE ON SURVIVAL OUTCOMES IN BREAST CANCER
    Jong-Ho Cheun
     (SMG-SNU Boramae Medical Center, Korea)
  • THE IMPACT OF CAVITARY MARGIN SHAVING OF BREAST CONSERVING SURGERY: THE ONCOLOGICAL OUTCOME
    Dabin Kim
     (Soonchunhyang Univ. Hospital Bucheon, Korea)
  • FUNCTIONALITY BETWEEN BREAST CONSERVATION SURGERY VS MASTECTOMY: SHORT TERM OUTCOME FROM A SINGLE INSTITUTION
    Lorraine Ma
     (Pamela Youde Nethersole Eastern Hospital, Hong Kong)
  • POST-OPERATIVE OUTCOMES OF ROBOT-ASSISTED NIPPLE-SPARING MASTECTOMY WITH IMMEDIATE BREAST RECONSTRUCTION REGARDING TO ROBOT SURGICAL SYSTEMS
    Jieon Go
     (Severance Hospital, Korea)
  • COMPARISON OF LONG-TERM ONCOLOGICAL OUTCOMES OF CENTRAL LUMPECTOMY AND CONVENTIONAL BREAST-CONSERVING SURGERY FOR INVASIVE BREAST CANCER
    Jijung Jung
     (Seoul National Univ., Korea)
  • RISK FACTOR OF SKIN AND NIPPLE-AREOLAR COMPLICATION AND ONCOLOGIC SAFETY IN DIFFERENT APPROACH NIPPLE SPARING MASTECTOMY: A LONG-TERM FOLLOW-UP IN A SINGLE MEDICAL CENTER
    Ruoh Yun Gau
     (Chang Gung Memorial Hospital, Taiwan)
  • LONG-TERM ONCOLOGICAL OUTCOMES OF ONCOPLASTIC BREAST-CONSERVING SURGERY AFTER A 10-YEAR FOLLOW-UP: A SINGLE CENTER EXPERIENCE AND SYSTEMATIC LITERATURE REVIEW
    Byeongju Kang
     (Kyungpook National Univ. Chilgok Hospital, Korea)
  • OCCULT LYMPH NODE METASTASES IN CLINICALLY NODE-NEGATIVE (CN0) BREAST CANCER PATIENTS REFERRED FOR NEOADJUVANT THERAPY (NAT).
    Si Ying Tan
     (Singapore General Hospital, Singapore)
  • GBCC-CACA Joint Session: 
    Programs for Breast Cancer Screening and Prevention44
  • Venue:  RM 5(Art Hall)
Moderators
  • Il Yong Chung
     (ASAN Medical Center, Korea)
  • Peng Yuan
     (Chinese Academy of Medical Sciences, Cancer Hospital, China)
Speakers
  • KBCS Guidelines of Screening and Current Status
    Young-Joon Kang
     (The Catholic Univ. of Korea, Incheon St. Mary's Hospital, Korea)
  • CACA Guidelines of Screening and Current Status
    Yongsheng Wang
     (Shandong Cancer Hospital & Institute, China)
  • Korean Recommendations for Prevention and Risk Managements
    Yoo Seok Kim
     (Chosun Univ. Hospital, Korea)
  • Chinese Recommendations for Prevention and Risk Managements
    Junjie Li
     (Fudan Univ. Shanghai Cancer Center, China)
Panelist
  • Discussion
    Kyung-Hun Lee
     (Seoul National Univ. Hospital, Korea)
  • Sung Eun Song
     (Korea Univ. Anam Hospital, Korea)
  • Yanxia Shi
     (Sun Yat-Sen Univ. Cancer Center, China)
  • Yu Ren
     (The First Affiliated Hospital of Xi'an Jiaotong Univ., China)



Global Breast Cancer Conference Secretariat

Partner I INTERCOM Convention Services, Inc. (Core PCO)

TOP